Clinical Trial Update: Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis [Phase 4]

View source ↗

Summary

Phase 4 study evaluating patient perceptions and quality of life associated with using olopatadine 0.2% for allergic conjunctivitis; results were posted in 2012…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Patanol (olopatadine hydrochloride)

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED | Results posted: 2012-04-03